Miller Anestesia

Óxido nítrico y vasodilatadores pulmonares inhalatorios

721

Sección II

Farmacología y anestesia

139. Frampton MW, Morrow PE, Cox C, et al: Effects of

nitrogen dioxide exposure on pulmonary function

and airway reactivity in normal humans. Am Rev

Respir Dis 143:522-527, 1991.

140. Centers for Disease Control and Prevention (CDC):

1988 NIOSH recommendations for occupational

safety and health standards. MMWR Morb Mortal

Wkly Rep 37(Suppl 7)1-29, 1988.

141. Clutton-Brock J: Two cases of poisoning by conta-

mination of nitrous oxide with higher oxides of

nitrogen during anaesthesia. Br J Anaesth 39:388-

392, 1967.

142. Weinberger B, Laskin DL, Heck DE, Laskin JD: The

toxicology of inhaled nitric oxide. Toxicol Sci 59:5-

16, 2001.

143. Kinsella JP, Truog WE, Walsh WF, et al: Randomi-

zed, multicenter trial of inhaled nitric oxide and

high-frequency oscillatory ventilation in severe,

persistent pulmonary hypertension of the newborn.

J Pediatr 131:55-62, 1997.

144. The Neonatal Inhaled Nitric Oxide Study Group:

Inhaled nitric oxide and hypoxic respiratory failure

in infants with congenital diaphragmatic hernia.

Pediatrics 99:838-845, 1997.

145. Loh E, Stamler JS, Hare JM, et al: Cardiovascular

effects of inhaled nitric oxide in patients with left

ventricular dysfunction. Circulation 90:2780-2785,

1994.

146. Brady AJ, Warren JB, Poole-Wilson PA, et al: Nitric

oxide attenuates cardiac myocyte contraction. Am J

Physiol 265:H176–H182, 1993.

147. Finkel MS, Oddis CV, Jacob TD, et al: Negative ino-

tropic effects of cytokines on the heart mediated by

nitric oxide. Science 257:387-389, 1992.

148. DicksteinML,Burkhoff D:A theoretic analysis of the

effect of pulmonary vasodilation on pulmonary

venous pressure: Implications for inhaled nitric oxide

therapy. J Heart Lung Transplant 15:715-721, 1996.

149. Hare JM, Shernan SK, Body SC, et al: Influence of

inhaled nitric oxide on systemic flow and ventricular

filling pressure in patients receiving mechanical cir-

culatory assistance. Circulation 95:2250-2253, 1997.

150. Lowson SM: Alternatives to nitric oxide. Br Med

Bull 70:119-131, 2004.

151. Walmrath D, Schneider T, Pilch J, et al: Aerosolised

prostacyclin in adult respiratory distress syndrome.

Lancet 342:961-962, 1993.

152. Haraldsson A, Kieler-Jensen N, Ricksten SE: The

additive pulmonary vasodilatory effects of inhaled

prostacyclin and inhaled milrinone in postcardiac

surgical patients with pulmonary hypertension.

Anesth Analg 93:1439-1445, 2001.

153. Yurtseven N, Karaca P, Kaplan M, et al: Effect of

nitroglycerin inhalation on patients with pulmo-

nary hypertension undergoing mitral valve replace-

ment surgery. Anesthesiology 99:855-858, 2003.

154. Mestan KKL, Carlson AD, White M, et al: Cardio-

pulmonary effects of nebulized sodium nitroprus-

side in term infants with hypoxic respiratory failure.

J Pediatr 143:640-643, 2003.

155. Sood BG, Delaney-Black V, Aranda JV, Shankaran

S: Aerosolized PGE

A selective pulmonary vasodi-

lator in neonatal hypoxemic respiratory failure:

Results of a phase I/II open label clinical trial.

Pediatr Res 56:579-585, 2004.

156. Olschewski H, Walmrath D, Schermuly R, et al:

Aerosolized prostacyclin and iloprost in severe pul-

monary hypertension. Ann Intern Med 124:820-

824, 1996.

157. Walmrath D, Schneider T, Schermuly R, et al: Direct

comparison of inhaled nitric oxide and aerosolized

prostacyclin in acute respiratory distress syndrome.

Am J Respir Crit Care Med 153:991-996, 1996.

158. Haraldsson A, Kieler-Jensen N, Nathorst-Westfelt

U, et al: Comparison of inhaled nitric oxide and

inhaled aerosolized prostacyclin in the evaluation

of heart transplant candidates with elevated pul-

monary vascular resistance. Chest 114:780-786,

1998.

159. van Heerden PV, Caterina P, Filion P, et al: Pulmo-

nary toxicity of inhaled aerosolized prostacyclin

therapy—an observational study. Anaesth Intensive

Care 28:161-166, 2000.

160. Morimatsu H, Goto K, Matsusaki T, et al: Rapid

development of severe interstitial pneumonia caused

by epoprostenol in a patient with primary pulmo-

nary hypertension. Anesth Analg 99:1205-1207,

2004.

161. Dickstein ML: Con: Inhaled prostaglandin as a pul-

monary vasodilator instead of nitric oxide. J Car-

diothorac Vasc Anesth 19:403-405, 2005.